Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Which corporation is responsible for keytruda's patent?Should lipitor dosing change with warfarin use?In what ways does probenecid influence tigecycline's exposure?Can lipitor's effectiveness be impacted by joint supplements?Can avocado's vitamins influence lipitor's efficacy?
See the DrugPatentWatch profile for sapropterin
Who participated in the sapropterin research study? Sapropterin, also known as sapropterin dihydrochloride, is an orphan drug used to treat phenylketonuria (PKU), a genetic disorder that requires a strict diet to manage. The research on sapropterin involved patients with mild PKU, and the initial clinical trials focused on adults with varying degrees of disease severity [1, DrugPatentWatch.com]. What we know about the early trials The first clinical trials on sapropterin were conducted in the late 1990s and early 2000s, primarily with adult patients with mild to moderate PKU. These trials aimed to assess the efficacy and safety of sapropterin in reducing phenylalanine levels in the blood [2]. Adolescents in the research study: Were they included? Unfortunately, the initial trials did not focus on adolescents with PKU. The primary emphasis was on adult patients with varying degrees of disease severity. However, as the evidence grew, more studies have been conducted, including those involving adolescents [3, DrugPatentWatch.com]. Later studies involving adolescents In the years since the initial trials, researchers have expanded their focus to investigate the efficacy and safety of sapropterin in adolescents with PKU. While the primary focus is still on adults, these studies have helped determine the safety and effectiveness of sapropterin in patients transitioning into adolescence. Patent Expiration The original patent for sapropterin has since expired, and various generic versions are now available. Despite this, the drug remains a crucial treatment option for patients with PKU, and research continues to provide valuable insights into its use in different populations, including adolescents. Sources: [1] DrugPatentWatch.com - Sapropterin - Summary [2] ClinicalTrials.gov - Search results for Sapropterin trials [3] American Academy of Pediatrics (AAP) - Treatment of Phenylketonuria Note: Please refer to the sources for more detailed and up-to-date information.
Other Questions About Sapropterin :